基本信息
views: 1136
Career Trajectory
Bio
Professor Ching-Lung Lai has applied himself to further the understanding and the treatment of chronic hepatitis B and its complications for over three decades. His studies and clinical trials have contributed significantly to advance the development of knowledge concerning the hepatitis B virus. He performed the first trial of interferon alpha in hepatitis B carrier children in 1987. He was one of the pioneering investigators in the use of nucleoside analogues, including phase 2 and 3 studies of lamivudine (1998), telbivudine (2007) and entecavir (2006). The phases III trials of these three antiviral agents were all published in the New England Journal of Medicine. He was amongst the first to appreciate that nucleoside analogues have to be taken on a long-term basis for continuing viral suppression. This is based on the results on studies of the natural history of his research group: that the majority of complications of chronic hepatitis B occur after HBeAg seroconversion because of continued viral replication. He re-defined the treatment endpoints for chronic hepatitis B; these findings were first presented in the State-of-the-Art Lecture in the AASLD in 2005 where he received a prolonged standing ovation. He has been invited to write the editorial for the phase 3 study of tenofovir (2008)
He and his research group have also carried out studies on the natural history of hepatocellular carcinoma and its treatment starting from 1979 onwards, occult hepatitis B and its implications as well as the long-term follow-up of hepatitis B vaccine recipients. He is still continuing with his research on hepatitis B, notably the use of newer treatment agents such as besifovir and the effect of long-term treatment on the levels of cccDNA in the hepatocytes.
He and his research group have also carried out studies on the natural history of hepatocellular carcinoma and its treatment starting from 1979 onwards, occult hepatitis B and its implications as well as the long-term follow-up of hepatitis B vaccine recipients. He is still continuing with his research on hepatitis B, notably the use of newer treatment agents such as besifovir and the effect of long-term treatment on the levels of cccDNA in the hepatocytes.
Research Interests
Papers共 888 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Frontiers in Drug Discovery (2022)
Backis A.,Khaplanov A.,Jebali R. Al, Ammer R., Apostolidis I.,Birch J.,Lai C. -C.,Deen P. P.,Etxegarai M., de Ruette N., Ramos J. Freita,Förster D. F.,
KIDNEYSno. 4 (2021): 261-268
BIOMEDICINESno. 8 (2021): 966-966
Cited14Views0Bibtex
14
0
Load More
Author Statistics
#Papers: 869
#Citation: 54445
H-Index: 109
G-Index: 211
Sociability: 9
Diversity: 1
Activity: 1
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn